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AML
• Characterized by an increase in 
the number of myeloid cells in 
the marrow and an arrest in 
their maturation
• Granulocytopenia, 
thrombocytopenia, or anemia
• leukocytosis. 
Epedemiology
• United States
•Annual incidence - 2.4 per 
100,000
•12.6 per 100,000 > 65 years
• Median age approx. 25 to 30 
years
• 5YSR <65 yr less than 40%
• Kosary CL, Ries LAG, Miller BA, Hankey BF, Edwards BK, eds. SEER 
cancer statistics review, 1973-1992: tables and graphs. Bethesda, Md.: 
National Cancer Institute, 1995

AML
• Primary 
• Secondary
• From CMML
• Myelodysplastic syndromes
• Chemotherapy  
• Congenital neutropenia, Blooms 
syndrome, Fanconis anemia 
Bone Marrow Audit: 
AKUH
• Feb 2003 to Feb 2006
• To determine the relative 
frequencies of hematological 
malignacies
• To establish the AML subtypes 
in our patients
Patients
• 356 pts
• 18 mo. To 91 yrs
• Male 180 (50.6%)
• Female 176 (49.4%)
Indications
• Anaemia 26.9%
• PUO 17.5%
• Pancytopenia 17.1%
• Possible leukemia 10.9%
• Leukoerythroblastic picture 
7.5%
• Staging lyphomas 6.1%
• Monocytopenias 5%
• Undetermined 9%
Findings
Disease Cases %
Acute myeloid leukemia 29 8.6%
Lymhoproliferative 
disorder
24 6.7%
Multiple myeloma 20 5.6%
Myeloproliferative 
disorder/myelodysplastic 
syndrome
9 2%
Metastatic tumour 9 2%
Acute lymphoblastic 6 1.7%
AML: FAB subtypes
• M0 – 2 (6.7%)
• M1- 7  (23%)
• M2 – 11(36%)
• M3 – 2 (6.7%0
• M4 – 5 (16%)
• M5 – 3 (10%)
• M6 - 1 (3.3%)
• M7 – 0 
AML: Patients 
characteristics
• Male – 18 (60%)
• Female – 12 (40%)
• Avg. age – 45yrs (22 – 85yrs)
Outcomes
• Declined treatment – 10
• Died while undergoing 
treatment – 8
• On follow up – 1
• Lost to follow up - 10
Outcomes
• Average hospital stay – 30 days
• Cost – avg Sh. 1.2m (564,000 –
2.6m)
Complications
• Severe thrombocytopenia 
• Febrile neutropenia
• Cellulitis
• Metrorrhagia
• Blood reaction
• Depression
• Diarrhoea
Complications
• Purulent conjunctivitis 
• UTI 
• Anemia
• Alopecia
Treatment
• Complete remission approx .65%
• Decreases with increasing age 
and the presence of unfavorable 
cytogenetic abnormalities.
• With postremission therapy, 
disease-free survival at five years 
ranges from 10 to 15% with low-
dose maintenance therapy to 25 
to 35% with intensive courses of 
chemotherapy
Chemotherapy
Adriamycin 70mg od *3/7
Cytosine arabinoside Ara-C 300mg 
od *5/7
Then
• Ara C 2g IV infusion x2/7
Complete Remission
• Blood neutrophil > 1500
• Plt > 100,000
• No blasts in circulation
• Bone marrow
• >20% trilineage maturation
• <5% blasts
Bone marrow transplant
• Allogeneic or autologous bone 
marrow transplant may not give 
any additional benefit to high 
dose cytarabine
• 740 pts, 70% went into 
remission
• More studies on the pipeline
• Nejm Volume 339:1649-1656
• 1998




